2023-08-14 06:06:13 ET
- Rockwell Medical press release ( NASDAQ: RMTI ): Q2 GAAP EPS of -$0.18 misses by $0.06 .
- Revenue of $18.1M (-3.1% Y/Y) beats by $0.02M .
- Cash and cash equivalents and investments available-for-sale at June 30, 2023 was $14.9 million compared to cash and cash equivalents and investments available-for-sale of $16.8 million at March 31, 2023 and $21.5 million at December 31, 2022.
- Outlook: Rockwell Medical increased its 2023 net sales guidance from between $78.0 million and $82.0 million to between $82.0 million and $86.0 million vs. consensus of $86.08M; and is increasing 2023 gross profit guidance from between $7.0 million and $9.0 million to between $8.0 million and $10.0 million.
- Along with synergies, Rockwell Medical expects this business to deliver 20% to 22% EBITDA margin to the Company.
For further details see:
Rockwell Medical reports mixed Q2 earnings; raises FY23 outlook